Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Oric Pharmaceuticals (ORIC) and Biogen (BIIB)

Tipranks - Tipranks - Thu Apr 2, 7:14AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), Oric Pharmaceuticals (ORIC) and Biogen (BIIB) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Inventiva (IVA)

In a report released today, Michael Yee from UBS reiterated a Buy rating on Inventiva, with a price target of $12.00. The company’s shares closed last Tuesday at $5.55.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -0.6% and a 42.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, MBX Biosciences, Inc., and Olema Pharmaceuticals. ;'>

Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $14.88, implying a 185.6% upside from current levels. In a report issued on March 19, Truist Financial also initiated coverage with a Buy rating on the stock with a $13.00 price target.

See today’s best-performing stocks on TipRanks >>

Oric Pharmaceuticals (ORIC)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Tuesday at $12.67.

According to TipRanks.com, Biegler is a 4-star analyst with an average return of 6.4% and a 41.3% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, BridgeBio Oncology Therapeutics, and Day One Biopharmaceuticals. ;'>

Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $20.30, a 60.6% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $18.00 price target.

Biogen (BIIB)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Biogen, with a price target of $275.00. The company’s shares closed last Tuesday at $183.33.

According to TipRanks.com, Olson is a 5-star analyst with an average return of 18.2% and a 45.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Madrigal Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $208.43 average price target, a 16.1% upside from current levels. In a report issued on March 30, TD Cowen also reiterated a Buy rating on the stock with a $215.00 price target.

Read More on IVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).